Current Headlines

  1. AGC To Expand GMP-Compliant Synthetic Pharmaceutical Intermediate And Active Ingredient Production Capacity Tenfold

    AGC Inc., a world-leading manufacturer of glass, chemicals and high-tech materials, announced on July 12 a major expansion of facilities at its Chiba Plant that will result in an approximately tenfold increase in the company's GMP(*1)-compliant synthetic pharmaceutical intermediate and active ingredient (*2) production capacity. The new capacity is set to come online in October 2019

  2. AbbVie Announces Submission Of Supplemental New Drug Application To US FDA For Venetoclax In Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible For Intensive Chemotherapy

    AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for venetoclax in combination with a hypomethylating agent (HMA) or in combination with low-dose cytarabine (LDAC) for the treatment of newly diagnosed patients with acute myeloid leukemia (AML) who are ineligible for intensive chemotherapy


  3. Cure Pharmaceutical Plans To Acquire Cannabinoid-Based Drug Pipeline From Therapix Biosciences Ltd.

    CURE Pharmaceutical (OTCQB:CURR), (“CURE”), an innovative drug delivery and development company, announced today that it has signed a term sheet with Therapix Biosciences Ltd. (Nasdaq:TRPX), (“Therapix”), a specialty, clinical-stage pharmaceutical company developing cannabinoid-based treatments, to acquire the non-pain assets of Therapix, subject to the completion of the related conditions. These assets include several clinical drug candidates as well as two pre-clinical drug candidates

  4. New Computational Method For Drug Discovery

    HITS researchers developed tauRAMD, a tool to predict drug-target residence times from short simulations

  5. Perlara Announces n=1 Drug Discovery Pact With Mission: Cure

    Perlara, a rare diseases drug discovery platform company partnering with highly motivated families, foundations and drug developers, today announced a PerlQuest partnership to cure chronic pancreatitis with Mission: Cure, a nonprofit organization whose mission is to find a cure and improve the quality of life for those affected by chronic pancreatitis and in the process, demonstrate a new, faster model for curing disease using innovative financing based on patient outcomes

  6. BioNTech And Genevant Sciences Sign Strategic mRNA-Focused Partnership In Rare Diseases

    BioNTech AG and Genevant Sciences recently announced that they have entered into a collaboration to develop five mRNA therapeutic programs for rare diseases with high unmet medical need

  7. Repurposed Drugs May Halt The Spread Of Cancer Cells

    For cancer cells to spread to other places in the body—or metastasize—they need to communicate with one another. One way they do this is through chemical messages delivered in exosomes, the molecules that carry information from cell to cell

  8. SRI International Announces Drug Research Collaboration With Ionis Pharmaceuticals

    SRI International today announced a research agreement with Ionis Pharmaceuticals, combining SRI's proprietary FOX Three Molecular Guidance cellular targeting system (MGS) with Ionis' proprietary antisense drug-discovery platform

  9. Cellectar’s CLR 131 Receives FDA Orphan Drug Designation For Treatment Of Ewing’s Sarcoma

    Cellectar Biosciences (Nasdaq:CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, announces that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to CLR 131, the company’s lead Phospholipid Drug Conjugate™ (PDC) product candidate, for the treatment of Ewing’s sarcoma, a rare pediatric cancer

  10. New Type Of Antibiotic Discovered

    A new type of antibiotic may offer a solution to millions of COPD patients and children with middle ear infections. The drug is unlikely to have side effects and also has the great advantage that no resistance development takes place